Literature DB >> 11980646

Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients.

Antonio Marchetti1, Nicola Tinari, Fiamma Buttitta, Antonio Chella, Carlo Alberto Angeletti, Rocco Sacco, Felice Mucilli, Axel Ullrich, Stefano Iacobelli.   

Abstract

90K, also known as Mac-2 binding protein, is a secreted glycoprotein that binds galectins, beta1-integrins, collagens, and fibronectin, and has some relevance in cell-cell and cell-extracellular matrix adhesion. Previous studies have shown that serum levels of 90K have prognostic value in several neoplasms. In the present study, the role of the expression of 90K as an adverse prognostic indicator in 72 pathological stage I non-small cell lung cancer patients was investigated immunohistochemically. All of the patients underwent complete surgical removal of the tumor. The median length of follow-up care was 54 months. High level of 90K expression (90K staining of > or =50% of the neoplastic cells) was observed in 20 of the 72 (28%) tumors. Expression of 90K was confirmed by ELISA. The results showed that a high expression of 90K correlates with adverse prognosis. Among patients with high 90K expression, the disease-free and overall survival rates were significantly lower than the same rates of those with low expression (P = 0. 0001 and P = 0. 0003, respectively). The incidence of distant metastases in the patients with high 90K expression (60%; 12 of 20 patients) was significantly higher than that of in the patients with low expression (21%; 11 of 53 patients; P = 0.0038). The results of multivariate analysis confirmed that a high 90K expression was a significant factor to predict poor prognosis. We suggest that 90K expression could be a useful prognostic factor in patients with stage I non-small cell lung cancer, likely as an indicator of the metastatic propensity of the tumor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980646

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Prevalidation of salivary biomarkers for oral cancer detection.

Authors:  David Elashoff; Hui Zhou; Jean Reiss; Jianghua Wang; Hua Xiao; Bradley Henson; Shen Hu; Martha Arellano; Uttam Sinha; Anh Le; Diana Messadi; Marilene Wang; Vishad Nabili; Mark Lingen; Darly Morris; Timothy Randolph; Ziding Feng; David Akin; Dragana A Kastratovic; David Chia; Elliot Abemayor; David T W Wong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-01       Impact factor: 4.254

2.  Quantitative Proteomics Reveals the Roles of Peroxisome-associated Proteins in Antiviral Innate Immune Responses.

Authors:  Mao-Tian Zhou; Yue Qin; Mi Li; Chen Chen; Xi Chen; Hong-Bing Shu; Lin Guo
Journal:  Mol Cell Proteomics       Date:  2015-06-29       Impact factor: 5.911

3.  A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma.

Authors:  Ayaka M Silverman; Rie Nakata; Hiroyuki Shimada; Richard Sposto; Yves A DeClerck
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

4.  SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.

Authors:  Manoj Kumar Kashyap; H C Harsha; Santosh Renuse; Harsh Pawar; Nandini A Sahasrabuddhe; Min-Sik Kim; Arivusudar Marimuthu; Shivakumar Keerthikumar; Babylakshmi Muthusamy; Kumaran Kandasamy; Yashwanth Subbannayya; Thottethodi Subrahmanya Keshava Prasad; Riaz Mahmood; Raghothama Chaerkady; Stephen J Meltzer; Rekha V Kumar; Anil K Rustgi; Akhilesh Pandey
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

5.  Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes.

Authors:  Rajaventhan Srirajaskanthan; Martyn E Caplin; Mark G Waugh; Jennifer Watkins; Tim Meyer; J Justin Hsuan; Nicholas J Beaumont
Journal:  Mol Cell Proteomics       Date:  2009-12-17       Impact factor: 5.911

6.  Salivary proteomics for oral cancer biomarker discovery.

Authors:  Shen Hu; Martha Arellano; Pinmanee Boontheung; Jianghua Wang; Hui Zhou; Jiang Jiang; David Elashoff; Roger Wei; Joseph A Loo; David T Wong
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

7.  Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.

Authors:  Ji Hee Lee; Myong-Suk Park; Jun-Eul Hwang; Sang-Hee Cho; Woo-Kyun Bae; Hyun-Jeong Shim; Dae-Eun Kim; Ik-Joo Chung
Journal:  Cell Mol Immunol       Date:  2013-03-25       Impact factor: 11.530

8.  Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old.

Authors:  Dilek Colak; Muhammad A Chishti; Al-Bandary Al-Bakheet; Ahmed Al-Qahtani; Mohamed M Shoukri; Malcolm H Goyns; Pinar T Ozand; John Quackenbush; Ben H Park; Namik Kaya
Journal:  Mol Cancer       Date:  2010-06-12       Impact factor: 27.401

9.  Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules.

Authors:  A Körner; G Mudduluru; C Manegold; H Allgayer
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

10.  Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane.

Authors:  Emina Emilia Torlakovic; Vicki Keeler; Chang Wang; Hyun J Lim; Leslie Ann Lining; Suzanne Laferté
Journal:  BMC Cancer       Date:  2009-07-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.